Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies
- PMID: 36864755
- PMCID: PMC10235899
- DOI: 10.1002/jcsm.13073
Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies
Abstract
Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the quality of life of cancer patients, decreases the efficiency of therapeutic strategies and ultimately contributes to decrease their lifespan. The depletion of skeletal muscle compartment, which represents the primary site of protein loss during cancer cachexia, is of very poor prognostic in cancer patients. In this review, we provide an extensive and comparative analysis of the molecular mechanisms involved in the regulation of skeletal muscle mass in human cachectic cancer patients and in animal models of cancer cachexia. We summarize data from preclinical and clinical studies investigating how the protein turnover is regulated in cachectic skeletal muscle and question to what extent the transcriptional and translational capacities, as well as the proteolytic capacity (ubiquitin-proteasome system, autophagy-lysosome system and calpains) of skeletal muscle are involved in the cachectic syndrome in human and animals. We also wonder how regulatory mechanisms such as insulin/IGF1-AKT-mTOR pathway, endoplasmic reticulum stress and unfolded protein response, oxidative stress, inflammation (cytokines and downstream IL1ß/TNFα-NF-κB and IL6-JAK-STAT3 pathways), TGF-ß signalling pathways (myostatin/activin A-SMAD2/3 and BMP-SMAD1/5/8 pathways), as well as glucocorticoid signalling, modulate skeletal muscle proteostasis in cachectic cancer patients and animals. Finally, a brief description of the effects of various therapeutic strategies in preclinical models is also provided. Differences in the molecular and biochemical responses of skeletal muscle to cancer cachexia between human and animals (protein turnover rates, regulation of ubiquitin-proteasome system and myostatin/activin A-SMAD2/3 signalling pathways) are highlighted and discussed. Identifying the various and intertwined mechanisms that are deregulated during cancer cachexia and understanding why they are decontrolled will provide therapeutic targets for the treatment of skeletal muscle wasting in cancer patients.
Keywords: Autophagy-lysosome; Cancer cachexia; Glucocorticoids; Inflammation; Myostatin; Oxidative stress; Proteostasis; Skeletal muscle; Ubiquitin-proteasome.
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Conflict of interest statement
A.M., Y.S.G. and D.F. declare that they have no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10235899/bin/JCSM-14-1150-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10235899/bin/JCSM-14-1150-g004.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10235899/bin/JCSM-14-1150-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10235899/bin/JCSM-14-1150-g002.gif)
Similar articles
-
Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.J Biol Chem. 2015 Apr 24;290(17):11177-87. doi: 10.1074/jbc.M115.641514. Epub 2015 Mar 18. J Biol Chem. 2015. PMID: 25787076 Free PMC article.
-
Myostatin is a novel tumoral factor that induces cancer cachexia.Biochem J. 2012 Aug 15;446(1):23-36. doi: 10.1042/BJ20112024. Biochem J. 2012. Retraction in: Biochem J. 2016 Apr 15;473(8):1111. doi: 10.1042/BJ4731111. PMID: 22621320 Free PMC article. Retracted.
-
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi: 10.1016/j.biocel.2013.05.019. Epub 2013 May 28. Int J Biochem Cell Biol. 2013. PMID: 23721881 Review.
-
Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFα/Myostatin Axis.Alcohol Clin Exp Res. 2020 Jan;44(1):66-77. doi: 10.1111/acer.14221. Epub 2019 Nov 11. Alcohol Clin Exp Res. 2020. PMID: 31657476 Free PMC article.
-
The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.Gen Comp Endocrinol. 2024 Jul 1;353:114513. doi: 10.1016/j.ygcen.2024.114513. Epub 2024 Apr 10. Gen Comp Endocrinol. 2024. PMID: 38604437 Review.
Cited by
-
The efficacy and safety of anamorelin among patients with diabetes.Int J Clin Oncol. 2024 Aug;29(8):1115-1121. doi: 10.1007/s10147-024-02546-8. Epub 2024 May 9. Int J Clin Oncol. 2024. PMID: 38722487
-
Common mouse models of chronic kidney disease are not associated with cachexia.Commun Biol. 2024 Mar 20;7(1):346. doi: 10.1038/s42003-024-06021-y. Commun Biol. 2024. PMID: 38509307 Free PMC article.
-
A triple-masked, two-center, randomized parallel clinical trial to assess the superiority of eight weeks of grape seed flour supplementation against placebo for weight loss attenuation during perioperative period in patients with cachexia associated with colorectal cancer: a study protocol.Front Endocrinol (Lausanne). 2024 Jan 19;14:1146479. doi: 10.3389/fendo.2023.1146479. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38313843 Free PMC article.
-
Body Composition in Chronic Liver Disease.Int J Mol Sci. 2024 Jan 12;25(2):964. doi: 10.3390/ijms25020964. Int J Mol Sci. 2024. PMID: 38256036 Free PMC article. Review.
-
Carnosol ameliorated cancer cachexia-associated myotube atrophy by targeting P5CS and its downstream pathways.Front Pharmacol. 2024 Jan 5;14:1291194. doi: 10.3389/fphar.2023.1291194. eCollection 2023. Front Pharmacol. 2024. PMID: 38249348 Free PMC article.
References
-
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495. - PubMed
-
- Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer‐associated cachexia. Nat Rev Dis Primers 2018;4:17105. - PubMed
-
- Cohn SH, Gartenhaus W, Sawitsky A, Rai K, Zanzi I, Vaswani A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism 1981;30:222–229. - PubMed
-
- Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, et al. Role of activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab 2015;100:2030–2038. - PubMed
-
- Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013;98:1012–1019. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous